Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Randomized Controlled Trial
. 2011 Oct 4:11:58.
doi: 10.1186/1471-2318-11-58.

Co-morbidity and drug treatment in Alzheimer's disease. A cross sectional study of participants in the dementia study in northern Norway

Fred Andersen  1 , Matti Viitanen, Dag S Halvorsen, Bjørn Straume, Torgeir A Engstad
Affiliations
Randomized Controlled Trial

Co-morbidity and drug treatment in Alzheimer's disease. A cross sectional study of participants in the dementia study in northern Norway

Fred Andersen et al. BMC Geriatr. .

Abstract

Background: Inappropriate medical treatment of co-morbidities in Alzheimer's disease (AD) is an increasing concern in geriatric medicine. The objective of this study was to compare current drug use related to co-morbidity between individuals with a recent diagnosis of AD and a cognitively healthy control group in a population based clinical trial in Northern Norway.

Setting: Nine rural municipalities with 70,000 inhabitants in Northern Norway.

Participants: PARTICIPANTS with and without AD recruited in general practice and by population based screening.187 participants with a recent diagnosis of AD were recruited among community dwellers. Of 791 respondents without cognitive symptoms, 500 were randomly selected and invited to further clinical and cognitive testing. The final control group consisted of 200 cognitively healthy individuals from the same municipalities. Demographic characteristics, data on medical history and current medication were included, and a physical and cognitive examination was performed. The statistical analyses were carried out by independent sample t-test, chi-square, ANCOVA and logistic regression.

Results: A co-morbidity score was significantly higher in AD participants compared to controls. The mean number of drugs was higher for AD participants compared to controls (5.1±3.6 and 2.9±2.4 respectively, p<0.001 age and gender adjusted), also when adjusted for co-morbidity. AD participants used significantly more anticholinergic, sedative and antidepressant drugs. For nursing home residents with AD the mean number of drugs was significantly higher compared to AD participants living at home (6.9±3.9 and 4.5±3.3, respectively, p<0.001).

Conclusions: AD participants were treated with a significantly higher number of drugs as compared to cognitively healthy controls, even after adjustment for co-morbidity. An inappropriate use of anticholinergic and sedative drugs was identified, especially among nursing home residents with AD. The drug burden and the increased risk of adverse reactions among individuals suffering from AD need more attention from prescribing doctors.

PubMed Disclaimer

Figures

Figure 1
Figure 1
Flowchart revealing recruitment methods and participants.
See this image and copyright information in PMC

References

    1. Aarsland D, Rongve A, Nore SP, Skogseth S, Skulstad S, Ehrt U, Hoprekstad D, Ballard C. Frequency and case identification of dementia with Lewy bodies using the revised consensus criteria. Dement Geriatr Cogn Disord. 2008;26:445–452. doi: 10.1159/000165917. - DOI - PubMed
    1. Bermejo-Pareja F, ito-Leon J, Vega S, Medrano MJ, Roman GC. Incidence and subtypes of dementia in three elderly populations of central Spain. J Neurol Sci. 2008;264:63–72. doi: 10.1016/j.jns.2007.07.021. - DOI - PubMed
    1. Ferrara M, Langiano E, Di BT, De VE, Di CL, Bauco C. Prevalence of stress, anxiety and depression in with Alzheimer caregivers. Health Qual Life Outcomes. 2008;6:93. doi: 10.1186/1477-7525-6-93. - DOI - PMC - PubMed
    1. Kivipelto M, Laakso MP, Tuomilehto J, Nissinen A, Soininen H. Hypertension and hypercholesterolaemia as risk factors for Alzheimer's disease: potential for pharmacological intervention. CNS Drugs. 2002;16:435–444. doi: 10.2165/00023210-200216070-00001. - DOI - PubMed
    1. Plassman BL, Langa KM, Fisher GG, Heeringa SG, Weir DR, Ofstedal MB, Burke JR, Hurd MD, Potter GG, Rodgers WL, Steffens DC, Willis RJ, Wallace RB. Prevalence of dementia in the United States: the aging, demographics, and memory study. Neuroepidemiology. 2007;29:125–132. doi: 10.1159/000109998. - DOI - PMC - PubMed

Publication types

Substances